Maraviroc: A Coreceptor CCR5 Antagonist for Management of HIV Infection

Raymond Yost; Timothy R. Pasquale; Eric G. Sahloff


Am J Health Syst Pharm. 2009;66(8):715-726. 

In This Article

Future Research

Data analysis continues on the 48-week Phase III MOTIVATE 1[46] and 2[47] and MERIT[48] clinical trials. Additional reports are also expected regarding the use of maraviroc in the dual- or mixed- and CXCR4-tropic populations.[49] A Phase III study is currently recruiting patients to evaluate the safety and tolerability of maraviroc in a more diverse population of HIV patients with no or limited treatment options due to treatment failure or intolerance.[50] A Phase II study is planned to evaluate the efficacy, safety, and tolerability of atazanavir-ritonavir with emtricita bine-tenofovir to a five-drug multiclass regimen including emtricitabine-tenofovir, atazanavir-ritonavir, maraviroc, and raltegravir in acutely HIV-1 infected, treatment-naive patients.[51] The primary outcome of this study is the percentage of patients having detectable viral loads after 48 weeks of treatment. Future studies are warranted to determine whether CCR5 antagonists induce tropism changes and if this change leads to disease progression. Additional studies evaluating maraviroc safety and efficacy in treatment-naive and treatment-experienced patients, as well as in pediatric, pregnant, and other special populations, are warranted.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as: